Saturna Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Saturna Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,553	Closed	-$44.6K	–	155
2025 Q3	$44.6K	Hold	20,553	–	–	﹤0.01%	157
2025 Q2	$35.4K	Hold	20,553	–	–	﹤0.01%	157
2025 Q1	$68.4K	Hold	20,553	–	–	﹤0.01%	149
2024 Q4	$152K	Hold	20,553	–	–	﹤0.01%	157
2024 Q3	$193K	Buy	20,553 +1,353	+7%	+$12.8K	﹤0.01%	157
2024 Q2	$154K	Sell	19,200 -6,000	-24%	-$64.3K	﹤0.01%	165
2024 Q1	$373K	Hold	25,200	–	–	0.01%	143
2023 Q4	$205K	Sell	25,200 -1,000	-4%	-$5.23K	﹤0.01%	170
2023 Q3	$119K	Buy	26,200 +6,000	+30%	+$39.2K	﹤0.01%	171
2023 Q2	$142K	Hold	20,200	–	–	﹤0.01%	163
2023 Q1	$123K	Buy	+20,200	New	+$139K	﹤0.01%	157

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Saturna Capital's IOVA Position: Q4 2025 in Review

Saturna Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2025, closing a stake of 20,553 shares — an estimated $44.6K sold.

Saturna Capital first reported a position in IOVA in Q1 2023 and held it in 11 quarters. The position peaked at $373K in Q1 2024. 263 funds tracked by Wall St. Rank hold IOVA as of Q4 2025.

Saturna Capital reported no remaining Iovance Biotherapeutics position as of Q4 2025 after selling out during the quarter.
Saturna Capital sold 20,553 Iovance Biotherapeutics shares in Q4 2025, an estimated $44.6K.
Saturna Capital first reported a position in Iovance Biotherapeutics in Q1 2023 and held it in 11 quarters.
Saturna Capital's Iovance Biotherapeutics position peaked at $373K in Q1 2024.
263 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2025.

Based on Saturna Capital's 13F filing for Q4 2025, filed 11 Feb 2026.